AR and prostate carcinoma: There are multiple nonsteroid ligands for AR that are developed for various endocrine therapeutic purposes, such as antiandrogens to treat prostate cancer (enzalutamide, apalutamide, darolutamide, and earlier flutamide and bicalutamide) and selective AR modulators (SARMs) for treating hypogonadal conditions in men.